

Dear Editors and Reviewers:

Thank you for your letter and for the reviewers' thoughtful comments concerning our manuscript entitled "Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report" (Manuscript NO: 59680). Those comments are all valuable and very helpful for revising and improving our paper. We have studied comments carefully and have made a careful revision on the original manuscript. The main corrections in the paper and the responds to the reviewers' comments are as following:

Responds to the reviewer's comments:

Reviewer #1:

1. **Comment 1:** *I would not include "case report" as a keyword, even that it reflects the type of the paper.*

Response: Thank you for your advice. We have removed the word "case report" from the keywords. (Line 24, page 3)

2. **Comment 2:** *Probably the legend of the images could insert more data about the results, not only the type of examination.*

Response: It is really true as you suggested that the legend of the images could insert more data. We have re-written the figure legends according to your thoughtful suggestion. (Line1-12, page 17)

3. **Comment 3:** *A minor correction at the first reference should be done (as the names are in Capital letters).*

Response: We are very sorry for our incorrect writing of the names at the first reference. We have made correction according to your comment. (Line18, page 10)

Responds to the editorial office's comments:

Comments 1: *I found the authors did not provide the approved grant application form(s). Please upload the approved grant application form(s) or funding agency copy*

of any approval document(s).

Response: Thank you very much. We have uploaded the approved grant application form(s) or funding agency copy of any approval document(s).

Comments 2: *I found the authors did not provide the original figures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.*

Response: Thank you so much. We have uploaded the original figure documents.

Comments 3: *I found the authors did not add the PMID and DOI in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout.*

Response: Thank you very much. We have added the PMID and DOI in the reference list.

We appreciate for editors/reviewers' careful work earnestly, and hope that the correction will meet with approval. Once again, thank you very much for your comments and suggestions.

Sincerely,

Yu Zhang

Corresponding author: Aiping Shi

E-mail: sap@jlu.edu.cn Department of Breast Surgery, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China

Point-by-point response for the second-round review

Dear Editor:

Thank you for your comment concerning our manuscript entitled “Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report” (Manuscript NO: 59680). We have made a careful revision on the manuscript according to the second-round review report. The main correction in the paper and the respond to the comment are as flowing:

Respond to the reviewer’s comment:

Comment 1: I would recommend to use the full name of disease (occult breast cancer) at the beginning of the text - INTRODUCTION (as in abstract) and then to use the abbreviation OBC.

Response: Thank you for your advice. We have made correction according to your comment and marked it in red in revised paper. (Line12, page 4) We appreciate for your careful work, and hope that the correction will meet with approval. Once again, thank you very much for your comments and suggestions.

Sincerely,

Yu Zhang Corresponding author: Aiping Shi E-mail: sap@jlu.edu.cn
Department of Breast Surgery, The First Hospital of Jilin University,
Changchun 130021, Jilin Province, China